The guidelines focused on idiopathic short stature, growth hormone deficiency, and primary IGF-I deficiency.
However, researcher says high cost, need to get shots in clinics make it an unlikely osteoporosis treatment.
The FDA has approved the FlexPro PenMate is intended for users of Norditropin, which is indicated for patients with growth hormone-related disorders, who prefer hidden needles during injection.
Use of performance-enhancing substances are not just bad for the image of sport, but they also don't improve athletes' performance.
Ferring announced that the FDA has approved the name changes of its newly acquired products to be marketed as Zomacton (somatropin [rDNA origin]; formerly Tev-Tropin) for injection, and the needle-free delivery system as Zoma-Jet (formerly Tjet).
Researchers have discovered a single gene in a region of the X chromosome that may cause excessive growth in children.
The Endocrine Society has issued a clinical practice guideline for the diagnosis and treatment of acromegaly.
Cardiovascular morbidity and mortality may be increased in people with higher values of fasting growth hormone.
Patients with growth hormone deficiency reaped significant benefits in quality of live over the long term.
Study showing increased GH use among teens may have inherent flaws.
The percentage of teens using human growth hormone has more than doubled since 2012.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation